Bevacizumab Receives New Labeled Indication

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 114, Nº. 12, 2014, págs. 25-26
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Bevacizumab (Avastin) is now approved to treat persistent, recurrent, or metastatic cervical cancer when given with one of two other approved drug therapies, paclitaxel and cisplatin or paclitaxel and topotecan.

    * The most common adverse effects noted in the phase 3 study of bevacizumab used to treat ovarian cancer were fatigue, decreased appetite, hypertension, hyperglycemia, hypomagnesemia, urinary tract infection, headache, and weight loss. Severe adverse effects are possible.